ArticleDiscover oncology2026
Exploring the role of IGHV3-30 in the immune microenvironment and prognosis of uterine endometrial cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUterine endometrial cancer (UCEC) is a major cause of morbidity and mortality in women, with a complex immune microenvironment influencing tumor progression and prognosis. This study aims to evaluate the prognostic significance of immune scores in UCEC, characterize immune cell infiltration patterns, and investigate the role of IGHV3-30 in the immune microenvironment and its association with clinical outcomes.
methodsWe performed bioinformatics analyses using TCGA data from 541 UCEC patients. Patients were stratified into high- and low-immune score groups based on optimal cutoffs determined by receiver operating characteristic (ROC) analysis. Immune microenvironment profiling was conducted using CIBERSORT and ESTIMATE algorithms. Differentially expressed genes (DEGs) were identified and analyzed for their association with immune cell infiltration, tumor stage, and prognosis. Somatic mutation analysis was also conducted to examine the relationship between IGHV3-30 expression and genetic alterations.
resultsHigh immune scores were significantly associated with favorable overall survival in UCEC patients, and decreased with advancing tumor stage.High expression of IGHV3-30 was significantly associated with favorable overall survival (OS) in UCEC patients. IGHV3-30 was identified at the intersection of differentially expressed genes (DEGs) and differentially mutated genes (DMGs) between immune groups.Additionally, IGHV3-30 expression correlated positively with the infiltration of immune cells such as M1 macrophages and plasma cells, and negatively with memory B cells and activated dendritic cells. Mutation analysis revealed that IGHV3-30 expression was linked to somatic mutations in key tumor suppressor genes.
conclusionImmune scores serve as valuable prognostic indicators in UCEC. IGHV3-30, predominantly expressed in B-cell lineages, demonstrates potential as a prognostic biomarker associated with favorable outcomes and distinct immune infiltration patterns. These findings provide insights for future immunotherapy strategies, though experimental validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.